Navigation Links
GSK Extends GeneGo License and Adds New Products
Date:2/5/2008

ST. JOSEPH, Mich., Feb. 5 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that GSK has extended their licensing agreement with GeneGo and have added additional capability. This will provide GSK researchers in Bioinformatics, R&D and clinical studies with global access to MetaCore, MapEditor and MetaBase. MetaCore is GeneGo's flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases. MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GSK will also use the platform as a repository of all types of experimental data as well as resulting analyses. All of this information can be easily shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating interactive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.

"We have a good working relationship with GSK developing new products such as our pay as you go 1-2-3 Workflow," said Julie Bryant, GeneGo's VP of Business development. "We will continue to work closely developing new functionality, tools and content for GSK."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Extends Tender Offer for Ventana
2. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
3. Organon Extends MetaCore License and Adds MetaLink
4. NASA Extends Cooperative Agreement With NSBRI
5. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
6. Roche Extends Tender Offer for Ventana
7. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
8. GeneGo Integrates With Cytoscape
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
10. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
11. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):